Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray

Study Overview
=================
Brief Summary
-----------------
The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

Detailed Description
-----------------
The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®). To directly compare patient satisfaction with 2 different Allergic Rhinitis nasal sprays, an observational, cross-sectional study design with 2 independent samples was chosen. Participants will complete an online survey involving a Best-Worst scaling (BWS) task to determine satisfaction and importance index for sensory attributes. The suggested treatment attributes are informed by a range of previous studies, including those conducted by Meltzer et al 2005 and Price et al 2020, and methodology from CaPPRe's own work in developing indices for importance and satisfaction of treatment attributes using BWS.

Official Title
-----------------
Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments for Allergic Rhinitis

Conditions
-----------------
Allergic Rhinitis

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study: Patients above 18 years old Fluent in English Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and currently using treatment Willing and able to provide consent to participate Exclusion Criteria: Have reported a loss of taste and/or smell related to COVID-19 (or other medical condition) Are employed by a pharmaceutical company (to avoid conflict of interest) Are employed by a vaccine company (to avoid conflict of interest) Do not have access to the internet (to ensure validity of the data) Are unable to read and understand English (to ensure validity of the data)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients on RYALTRIS<br>Patients who are currently using RYALTRIS nasal spray. | Other: Observational<br>* In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.<br>|
| Patients on DYMISTA<br>Patients who are currently using DYMISTA nasal spray. | Other: Observational<br>* In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Best-Worst Scaling task index score | The primary study endpoint is the overall index score from the Best Worst Scaling exercise, to reflect satisfaction and importance of treatment attributes of the RYALTRIS® and DYMISTA® nasal spray. Index scores from the Best Worst Scaling exercise range from 0 to 100, with higher scores indicating higher satisfaction of treatment attributes. | Cross-sectional - through study completion, an average of 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Domain scores from Best-Worst Scaling task | Secondary study endpoints are the Best Worst Scaling domain scores from the Best Worst Scaling exercise (i.e., relative ranking scores for each of the domains; satisfaction and importance). Best-Worst Scaling domain scores range from -1 to 1 and represent the relative ranking (ordering) of the domains. A negative score indicates the domain was chosen as worst more often than best. A positive score indicates the domain was chosen as best more often than worst. A zero score indicates the domain was chosen as best and worst an equal number of times OR was never chosen. | Cross-sectional - through study completion, an average of 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patient preference, Best-Worst Scaling, Treatment attributes